The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States
Open accessAbstract
BACKGROUND: Hepatocellular carcinoma (HCC) incidence has been increasing in the United States for several decades; and, as the incidence of hepatitis C virus (HCV) infection declines and the prevalence of metabolic disorders rises, the proportion of HCC attributable to various risk factors may be changing. METHODS: Data from the Surveillance, Epidemiology, and End Results‐Medicare linkage were used to calculate population attributable fractions (PAFs) for each risk factor over time. Patients with HCC (n = 10,708) who were diagnosed during the years 2000 through 2011 were compared with a 5% random sample of cancer‐free controls (n = 332,107) residing in the Surveillance, Epidemiology, and End Results areas. Adjusted odds ratios (ORs) and PAFs were calculated for HCV, hepatitis B virus (HBV), metabolic disorders, alcohol‐related disorders, smoking, and genetic disorders. RESULTS: Overall, the PAF was greatest for metabolic disorders (32%), followed by HCV (20.5%), alcohol (13.4%), smoking (9%), HBV (4.3%), and genetic disorders (1.5%). The PAF for all factors combined was 59.5%. PAFs differed by race/ethnicity and sex. Metabolic disorders had the largest PAF among Hispanics (PAF, 39.3%; 95% confidence interval [CI], 31.9%‐46.7%) and whites (PAF, 34.8%; 95% CI, 33.1%‐36.5%), whereas HCV had the largest PAF among blacks (PAF, 36.1%; 95% CI, 31.8%‐40.4%) and Asians (PAF, 29.7%; 95% CI, 25.9%‐33.4%). Between 2000 and 2011, the PAF of metabolic disorders increased from 25.8% (95% CI, 22.8%‐28.9%) to 36% (95% CI, 33.6%‐38.5%). In contrast, the PAFs of alcohol‐related disorders and HCV remained stable. CONCLUSIONS: Among US Medicare recipients, metabolic disorders contribute more to the burden of HCC than any other risk factor, and the fraction of HCC caused by metabolic disorders has increased in the last decade. Cancer 2016;122:1757‐65. Published 2016. This article is a U.S. Government work and is in the public domain in the USA..
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Estimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Global burden of COPD: risk factors, prevalence, and future trends
Mannino, D. M., & Buist, A. S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61380-4 · Cited by 2,079
Ott, J. J., Stevens, G. A., Groeger, J., & Wiersma, S. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.116 · Cited by 1,843
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Self-citationSmoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
Estimating the population attributable risk for multiple risk factors using case-control data.
BRUZZI, P., GREEN, S. B., BYAR, D. P., BRINTON, L. A., & SCHAIRER, C. (1985) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114174 · Cited by 1,214
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Cited by
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
Global Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3055 · Cited by 1,987
Islami, F., Goding Sauer, A., Miller, K. D., Siegel, R. L., Fedewa, S. A., Jacobs, E. J., McCullough, M. L., Patel, A. V., Ma, J., Soerjomataram, I., et al. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21440 · Cited by 1,610
Cancer health disparities in racial/ethnic minorities in the United States
Zavala, V. A., Bracci, P. M., Carethers, J. M., Carvajal-Carmona, L., Coggins, N. B., Cruz-Correa, M. R., Davis, M., de Smith, A. J., Dutil, J., Figueiredo, J. C., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01038-6 · Cited by 912
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Massarweh, N. N., & El-Serag, H. B. (2017) · Cancer Control · doi:10.1177/1073274817729245 · Cited by 634
International trends in hepatocellular carcinoma incidence, 1978–2012
Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., Ferlay, J., Valery, P. C., Bray, F., & McGlynn, K. A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32723 · Cited by 594
“5%).(45) While the obesity epidemic has been longstanding in the US, obesity rates are increasing in both developed and developing countries.”
BackgroundSelf-citationUpdate in global trends and aetiology of hepatocellular carcinoma
Rawla, P., Sunkara, T., Muralidharan, P., & Raj, J. P. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.78941 · Cited by 332
Projections of primary liver cancer to 2030 in 30 countries worldwide
Valery, P. C., Laversanne, M., Clark, P. J., Petrick, J. L., McGlynn, K. A., & Bray, F. (2018) · Hepatology · doi:10.1002/hep.29498 · Cited by 330
Self-citationAlcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease
Åberg, F., Byrne, C. D., Pirola, C. J., Männistö, V., & Sookoian, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.030 · Cited by 307
Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors
Baecker, A., Liu, X., La Vecchia, C., & Zhang, Z.-F. (2018) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000428 · Cited by 275
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Abrams, T. A., Alberts, S. R., Anaya, D. A., Anders, R., Are, C., Brown, D., Chang, D. T., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0019 · Cited by 269
Simon, T. G., King, L. Y., Chong, D. Q., Nguyen, L. H., Ma, Y., VoPham, T., Giovannucci, E. L., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., et al. (2018) · Hepatology · doi:10.1002/hep.29660 · Cited by 160
Bogumil, D., Park, S., Le Marchand, L., Haiman, C. A., Wilkens, L. R., Boushey, C. J., & Setiawan, V. W. (2019) · Hepatology Communications · doi:10.1002/hep4.1313 · Cited by 52
Liu, Y., Yang, W., VoPham, T., Ma, Y., Simon, T. G., Gao, X., Chan, A. T., Meyerhardt, J. A., Giovannucci, E. L., & Zhang, X. (2021) · Hepatology · doi:10.1002/hep.31251 · Cited by 40
Metadata
- Authors
- Makarova‐Rusher, O. V., Altekruse, S. F., McNeel, T. S., Ulahannan, S., Duffy, A. G., Graubard, B. I., Greten, T. F., & McGlynn, K. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-03-21
- Volume
- 122
- Issue
- 11
- Pages
- 1757-1765
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2310375888
- Cited by
- 332
- References
- 37
- FWCI
- 20.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.